北京康明海慧生物科技

Beijing Kangming Haihui Biotechnology is a biotechnology company focused on the development of innovative gene therapies, operating as a subsidiary of Chengdu Kanghong Pharmaceutical Group. The company specializes in adeno-associated virus (AAV) vector technologies to address high-unmet-need diseases in ophthalmology and oncology. Its lead candidate, KH631, is a gene therapy for neovascular age-related macular degeneration (nAMD) that has entered clinical trials in both China and the United States. Kangming Haihui leverages a robust R&D platform to design long-acting treatments that potentially reduce the burden of frequent intravitreal injections. The company is a key component of Kanghong's strategic expansion into the global gene therapy market.